1. Home
  2. ICUCW vs GNLX Comparison

ICUCW vs GNLX Comparison

Compare ICUCW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SeaStar Medical Holding Corporation Warrant

ICUCW

SeaStar Medical Holding Corporation Warrant

HOLD

Current Price

$0.01

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$4.34

Market Cap

202.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUCW
GNLX
Founded
N/A
2001
Country
United States
United States
Employees
18
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
202.4M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
ICUCW
GNLX
Price
$0.01
$4.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.75
AVG Volume (30 Days)
N/A
118.5K
Earning Date
N/A
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.99
52 Week High
N/A
$8.54

Technical Indicators

Market Signals
Indicator
ICUCW
GNLX
Relative Strength Index (RSI) 40.41 41.11
Support Level $0.01 $4.21
Resistance Level $0.01 $4.46
Average True Range (ATR) 0.00 0.25
MACD 0.00 0.06
Stochastic Oscillator 50.00 46.90

Price Performance

Historical Comparison
ICUCW
GNLX

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Share on Social Networks: